The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Charles Swanton
Stock and Other Ownership Interests - Apogen Biotechnologies; Epic Sciences
Honoraria - Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Ono Pharmaceutical; Roche; SERVIER
Research Funding - Boehringer Ingelheim
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Howard A. Burris
No Relationships to Disclose
 
Ron Bose
Honoraria - Genentech; Novartis
Consulting or Advisory Role - Genentech
 
Shuangli Guo
No Relationships to Disclose
 
Coen Bernaards
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Mary Stanley Beattie
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Alisha Stein
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Melissa Brammer
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Razelle Kurzrock
Leadership - RScueRx Inc
Stock and Other Ownership Interests - Actuate Therapeutics; RScueRx
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Janssen; Jubilant Biosys; NCCN; NXT Health Strategies; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; The Dedham Group; UCSD Genomics Program Talk
Consulting or Advisory Role - AACR; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom
Speakers' Bureau - Guardant Health
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; EMD Serono; EMD Serono & Quintiles; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Global Biomarkers Consortium; ICRP; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma